Industry news

In Moscow, new laser to treat eye diseases

Marchmont Innovation News

Scientists at the Moscow Lomonosov State University (MSU) in partnership with colleagues from the Belarus National Technical University in neighboring Belarus have come up with what they claim is a unique laser to treat eye diseases, portal Hi-tech.mail.ru  reported . 

26 April 2016

Clearside Biomedical, Inc. Announces Positive Preliminary Phase 2 Results in Patients With Macular Edema Associated with Retinal Vein Occlusion

Сlearside Biomedical, Inc. today announced that its Phase 2 clinical trial evaluating concomitant administration of suprachoroidal ZUPRATA™, Clearside’s proprietary form of triamcinolone acetonide, together with intravitreal aflibercept (EYLEA®), for the treatment of macular edema associated with retinal vein occlusion (RVO), achieved its primary endpoint.

Europe plans $7.5B region-wide cloud system to connect scientists

Nick Paul Taylor / Fierce Biotech

European politicians are working to create a cloud platform on which the 1.7 million researchers and 70 million science and technology professionals in the region can store and share data. The plan is to eliminate digital barriers between scientists by establishing the European Union at the forefront of high-performance computing.

'Breakthrough' confusion prompts FDA to explain its terms

Beth Snyder Bulik / FiercePharmaMarketing

What does "breakthrough" mean? The FDA set out to explain the designation last week after academic studies and the media reported widespread confusion about the term.

New drugs for hepatitis and diabetes may come from Siberia

Marchmont Innovation News

In Siberia, scientists have leveraged years of research into the properties of stem cells in a new project aimed at developing new drugs to fight hepatitis and diabetes. 

EuroBiotech Report: MedCity forecasts shortfall in London lab space

Nick Paul Taylor / Fierce Biotech

Welcome to the latest edition of our weekly EuroBiotech Report. We start this week in London, where a report from MedCity highlighted the difficulties of trying to fit a growing biotech sector into an already congested city. 

States' efforts to fight skyrocketing costs pose 'modest risk to pharma': Report

Emily Wasserman / FiercePharma

States across the country have been battling it out with Big Pharma over drug pricing, with some introducing bills that take aim at skyrocketing costs. People on both sides of the issue are wondering whether the states’ efforts will pay off, and now, some analysts have an answer: “probably not.”

Pharma digital spending ticks upward slowly but surely

Beth Snyder Bulik / FiercePharmaMarketing

Digital spending is expected to overtake TV media spending in the advertising industry this year, but for the pharma industry that’s not nearly true yet. Drug marketers are beginning to shift, however, if only at the slow speed customary in the pharma world.

BBA formed to help U.K. catch up on biosimilars scene

Nuala Moran / BioWorld

Biosimilars companies have joined forces to drive uptake of their products in the U.K., securing the backing of the National Health Service's (NHS) chief pharmaceutical officer in a push to promote competition against higher-price originators.

Money from home: European biotech turns back to home turf

Cormac Sheridan / BioWorld

Even if the U.S. public markets are cooling on European biotech, a clutch of recent transactions suggests that companies' home markets still remain supportive. Financing activity has been sluggish this year, in contrast with last year, but a trickle of cash is still flowing into European biotech.